# Teva Branded Pharmaceutical Products trials: 206 (2026)

ClinicalTrials.gov lists 206 trials with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Teva Branded Pharmaceutical Products R&D, Inc.: 206 rows for $10.30, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/teva-branded-pharmaceutical-products-r-and-d-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 206
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 206, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 4, 2024 | NCT06627231 | Mass Balance Clinical Trial With TEV-56286 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06627231) |
| March 4, 2024 | NCT06290102 | Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | Asthma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06290102) |
| August 12, 2022 | NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Completed | Crohn Disease, Colitis, Ulcerative | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05499130) |
| July 14, 2022 | NCT05458011 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Migraine | 365 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05458011) |
| April 19, 2021 | NCT04847674 | A Study to Test if TEV-53275 is Effective in Relieving Asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Terminated | Asthma | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04847674) |
| December 23, 2020 | NCT04682353 | A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | Contraception | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04682353) |
| December 21, 2020 | NCT04677959 | A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 | Completed | Asthma | 427 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04677959) |
| September 11, 2020 | NCT04545385 | A Study to Test if TEV-48574 is Effective in Relieving Asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Terminated | Asthma | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04545385) |
| July 9, 2020 | NCT04464707 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Migraine | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04464707) |
| July 7, 2020 | NCT04458857 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Migraine | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04458857) |
| June 25, 2020 | NCT04447729 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Withdrawn | Interstitial Cystitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04447729) |
| December 16, 2019 | NCT04200352 | A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Terminated | Cerebral Palsy, Dyskinetic | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04200352) |
| August 1, 2019 | NCT04041284 | A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 | Completed | Migraine, Major Depressive Disorder | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04041284) |
| May 28, 2019 | NCT03965091 | A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Terminated | Fibromyalgia | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03965091) |
| March 28, 2019 | NCT03893825 | A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Schizophrenia | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03893825) |
| March 26, 2019 | NCT03890666 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 | Completed | Asthma | 333 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03890666) |
| January 23, 2019 | NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Cerebral Palsy, Dyskinetic | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03813238) |
| October 9, 2018 | NCT03700658 | A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 | Completed | Contraception | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03700658) |
| June 27, 2018 | NCT03571256 | A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS) | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Tourette Syndrome | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03571256) |
| June 25, 2018 | NCT03567291 | Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Terminated | Tourette Syndrome | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03567291) |
| April 19, 2018 | NCT03503318 | Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Schizophrenia | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03503318) |
| March 2, 2018 | NCT03452943 | Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2/3 | Completed | Tourette Syndrome | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03452943) |
| November 20, 2017 | NCT03347188 | A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH) | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | Completed | Post-Traumatic Headache | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03347188) |
| October 13, 2017 | NCT03308968 | An Efficacy and Safety Study of Fremanezumab in Adults With Migraine | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Migraine Prophylaxis | 838 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03308968) |
| August 22, 2017 | NCT03256695 | Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants... | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | Completed | Chronic Obstructive Pulmonary Disease | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03256695) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 31 |
| Phase 1/2 | 6 |
| Phase 2 | 51 |
| Phase 2/3 | 2 |
| Phase 3 | 90 |
| Phase 4 | 15 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 169 |
| Terminated | 30 |
| Withdrawn | 7 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 44 |
| Parkinson Disease | 14 |
| Multiple Sclerosis, Relapsing-Remitting | 12 |
| Multiple Sclerosis | 11 |
| Migraine Disorders | 9 |
| Pulmonary Disease, Chronic Obstructive | 7 |
| Pulmonary Eosinophilia | 5 |
| Rhinitis, Allergic, Seasonal | 4 |
| Dwarfism, Pituitary | 4 |
| Glioblastoma | 4 |
| Huntington Disease | 4 |
| Rhinitis, Allergic, Perennial | 4 |
| Rhinitis, Allergic | 4 |
| Pain | 3 |
| Crohn Disease | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Lupus Erythematosus, Systemic | 3 |
| Osteoarthritis | 3 |
| Cluster Headache | 3 |
| Tourette Syndrome | 3 |
| Low Back Pain | 3 |
| Neuralgia, Postherpetic | 2 |
| Neutropenia | 2 |
| Schizophrenia | 2 |
| Movement Disorders | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
